Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback